Searchable abstracts of presentations at key conferences in endocrinology

ea0084ps2-06-52 | Hypothyroidism Treatment | ETA2022

The effect on serum tsh levels in patients in treatment with proton pump inhibitors after the switch from oral L-T4 tablet to a liquid L-T4 formulation

Fallahi Poupak , Martina Ferrari Silvia , Elia Giusy , Ragusa Francesca , Rosaria Paparo Sabrina , Mazzi Valeria , Antonelli Alessandro

Objective: The treatment with proton pump inhibitors (PPI; omeprazole, pantoprazole, lansoprazole) used for gastritis, gastric ulcer, etc. could lead to L-thyroxine (L-T4) malabsorption issues, that is induced by the increased gastric pH. Many factors like age, way of assumption (during breakfast or with food), other drugs interferences, drug-kinetics, adherence to therapy, could impair the L-T4 absorption.Methods: The study involved 27 hypothyroid patie...

ea0084ps2-06-50 | Hypothyroidism Treatment | ETA2022

TSH levels assessment in hypothyroid patients treated with liquid or tablet l-thyroxine

Antonelli Alessandro , Martina Ferrari Silvia , Elia Giusy , Ragusa Francesca , Rosaria Paparo Sabrina , Mazzi Valeria , Botrini Chiara , Fallahi Poupak

Objective: Tablet levothyroxine (L-T4) is the common used therapy for hypothyroidism. In order to assess a good compliance to the therapy, treated patients are monitored with the execution of annual thyroid hormonal test. The stability of TSH levels in hypothyroid patients (with no malabsorption issues), treated with liquid L-T4, compared to that of the patients treated with tablet L-T4, remained a poorly understood topic. This study has the purpose to deepen this issue.<p...

ea0084ps2-07-63 | Graves’ Disease 1 | ETA2022

Corticosteroids and mycophenolic acid have a synergistic effect on chemokines secretion in orbital cells from patients with graves’ ophthalmopathy

Martina Ferrari Silvia , Fallahi Poupak , Ragusa Francesca , Elia Giusy , Rosaria Paparo Sabrina , Patrizio Armando , Balestri Eugenia , Antonelli Alessandro

Objective: An enhancement of the response rate has been recently showed in patients with Graves’ ophthalmopathy (GO) treated with corticosteroids and mycophenolic acid. In GO, retro-orbital cells showed a cytokine-induced secretion of Th1 and Th2 chemokines. Since no data are present in literature about the effect of corticosteroids and mycophenolic acid on the chemokines secretion in GO orbital cells, we aim to deepen out this topic.Methods: We est...

ea0090oc2.6 | Oral Communications 2: Thyroid | ECE2023

CD3+CD8+CD20+T lymphocytes behave differently in autoimmune thyroiditis and related polyautoimmune disorders: A pilot study

Stramazzo Ilaria , Mangino Giorgio , Fallahi Poupak , Santaguida Maria Giulia , Gargano Lucilla , Capriello Silvia , Virili Camilla , Centanni Marco

The presence and the role of CD20+ T cells in humans has been described in autoimmune disorders such as multiple sclerosis and rheumatoid arthritis. In healthy subjects, CD3+CD20+ T cells are detected in all lymphatic organs and in the cerebrospinal fluid and represent about 5% of circulating T cells. Some reports described their production of high levels of IL-17A and/or IFN-γ. This study was aimed at investigating the behavior of CD3<sup...

ea0092ps3-25-07 | Case Reports 2 | ETA2023

A case report of graves’ disease induced by IFN-β-1a therapy

Patrizio Armando , Viva Tommaso , Martina Ferrari Silvia , Elia Giusy , Ragusa Francesca , Rosaria Paparo Sabrina , Antonelli Alessandro , Fallahi Poupak

The risk of thyroid dysfunction induced by Interferon (IFN)-β1b therapy, in particular in patients having preexisting thyroid autoimmune disorders (AITD), is well known. We report a case of a 60-year-old female, with a 15-year history of euthyroid autoimmune thyroiditis and a 3-year history of Multiple Sclerosis (MS), in care for the evaluation of hyperthyroidism. The patient started a specific immunomodulant IFN-β1a therapy (30 μg/week) twenty months before the...

ea0081ep1138 | Thyroid | ECE2022

Autoimmune thyroiditis and hypothyroidism: a personalized medical approach

Martina Ferrari Silvia , Ragusa Francesca , Elia Giusy , Paparo Sabrina Rosaria , Mazzi Valeria , Balestri Eugenia , Botrini Chiara , Patrizio Armando , Antonelli Alessandro , Fallahi Poupak

Autoimmune thyroid diseases (AITD) are organ specific autoimmune disorders with a T-cell-mediated immune attack directed against the thyroid. Hashimoto’s thyroiditis and Graves’ disease are the two principal AITD clinical presentations, which are characterized by hypothyroidism and thyrotoxicosis, respectively. We review the available data in literature about personalized medicine in patients with autoimmune thyroiditis (AT) and hypothyroidism. The synthetic Levothyr...

ea0037ep867 | Thyroid cancer | ECE2015

The two tyrosine kinase inhibitors, CLM29 and CLM3, have antineoplastic activity in primary cultures from anaplastic thyroid cancer obtained from fine needle aspiration

Ferrari Silvia Martina , Fallahi Poupak , Motta Concettina La , Materazzi Gabriele , Ragusa Francesca , Limongi Francesca , Ruffilli Ilaria , Settimo Federico Da , Miccoli Paolo , Antonelli Alessandro

Anaplastic thyroid cancer (ATC) is one of the most lethal endocrine malignancy, with a mean survival of about 6 months. Until now, the most effective therapy for ATC comprises a multimodal treatment protocol, including surgery, chemotherapy (doxorubicin and cisplatin), and hyperfractionated accelerated external beam radiotherapy, with a median patient survival of 10 months. A possible increase in the effectiveness of the treatment could be achieved testing the sensitivity of &...

ea0032p1081 | Thyroid cancer | ECE2013

A novel multi-target pyrazolopyrimidine derivative with anti-neoplastic properties, CLM29, is active against medullary thyroid cancer in vitro and in vivo

Fallahi Poupak , Ferrari Silvia Martina , Bocci Guido , La Motta Concettina , Ruffilli Ilaria , Di Domenicantonio Andrea , Corrado Alda , Mancusi Caterina , Danesi Romano , Da Settimo Federico , Miccoli Paolo , Antonelli Alessandro

Introduction: CLM29, a pyrazolo[3,4-d]pyrimidine compound, inhibits several targets (including the RET tyrosine kinase, epidermal growth factor receptor, vascular endothelial growth factor receptor and has an anti-angiogenic effect). Recently it has been shown to inhibit proliferation and migration in primary papillary dedifferentiated thyroid cancer cells. The aim of this study is to evaluate the anti-tumor activity of CLM29 in medullary thyroid cancer (MTC).<p c...

ea0092ps3-21-06 | Hypothyroidism | ETA2023

Liquid Levothyroxine (L-T4; vs. Tablet L-T4) mantains more stable tsh levels in hypothyroid patients

Fallahi Poupak , Martina Ferrari Silvia , Elia Giusy , Ragusa Francesca , Rosaria Paparo Sabrina , Balestri Eugenia , Botrini Chiara , Patrizio Armando , Mazzi Valeria , Antonelli Alessandro

Hypothyroidism is usually treated with levothyroxine (L-T4), that is present in different formulation. We aim to assess if hypothyroid patients have a better control of thyroid-stimulating hormone (TSH) levels by following a L-T4 therapy in a liquid formulation, with respect to the tablet formulation. We enrolled seven hundred hypothyroid patients treated with liquid L-T4, and three hundred and fifty hypothyroid subjects receiving tablet L-T4 (both groups were matched by age a...

ea0092ps3-21-09 | Hypothyroidism | ETA2023

Efficacy of oral liquid l-thyroxine (L-T4) in controlling hypothyroidism in patients submitted to total thyroidectomy

Ragusa Francesca , Fallahi Poupak , Martina Ferrari Silvia , Elia Giusy , Materazzi Gabriele , Rosaria Paparo Sabrina , Patrizio Armando , Mazzi Valeria , Miccoli Paolo , Antonelli Alessandro

Tablet levothyroxine (L-T4) is the common treatment for hypothyroidism. We aim to investigate the efficacy of L-T4 in liquid formulation in patients recently subjected to total thyroidectomy (without malabsorption or drug interference), with respect to L-T4 tablets. Eighty patients were treated with L-T4 in tablets, whereas one hundred and sixty received liquid L-T4 at the same dosage (1.5 mg/kg/day). All patients started the therapy the day after thyroidectomy, and the drugs ...